DALTON, Ga. – The latest developments in
stroke treatments was the topic of a recent
informational presentation at Hamilton Medical
Center (HMC) attended by physicians, nurses and
other clinical staff members.
As part of his presentation, stroke specialist Thomas Devlin, MD, of Erlanger Health System, discussed recent endovascular trial results and the identification of stroke patients that would benefit from endovascular treatment.
“We’re always working on providing the most advanced stroke care,” said Hannah Jones, RN, HMC clinical resource nurse. “That’s why we host this type of specialized stroke presentation at Hamilton.”
In 2014, HMC received the Get With The Guidelines®-Stroke Silver-Plus Quality Achievement Award for implementing specific quality improvement measures outlined by the American Heart Association/American Stroke Association for the treatment of stroke patients.
HMC also received the association’s Target: Stroke Honor Roll for meeting stroke quality measures that reduce the time between hospital arrival and treatment with the clot-buster tPA, the only drug approved by the U.S. Food and Drug Administration to treat ischemic stroke. People who suffer a stroke who receive the drug within three hours of the onset of symptoms may recover quicker and are less likely to suffer severe disability.
According to the American Heart Association/American Stroke Association, stroke is the number four cause of death and a leading cause of adult disability in the United States. On average, someone suffers a stroke every 40 seconds; someone dies of a stroke every four minutes; and 795,000 people suffer a new or recurrent stroke each year.
|At a recent stroke treatment presentation at Hamilton Medical Center, from left, are Candace Mahoney, RN, BSN, Erlanger stroke coordinator; Jill McKenzie, RN, Erlanger stroke coordinator; Thomas Devlin, MD, Erlanger; Kimberly Smith, MD, Hamilton Neurology Associates; Hannah Jones, RN, clinical resource nurse; Jonathan Thompson, MD, Hamilton Medical Center Emergency Department medical director; and Robert Pedersen, MD, neurohospitalist.|